Zim Laboratories share price today

Zim Laboratories Ltd's share price was ₹134.43 at the close on 4 November 2026. It has been rising for 24 weeks. That is 21.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹64 and ₹151, and at that close it sat 81% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Zim Laboratories Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 13 weeks in a row.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

One change stood out: lowest operating margin in 15 quarters.

1. Lowest operating margin in 15 quarters

   Operating margin was 2.6% in the June 2026 quarter, against 5.9% a year earlier.

   Why: The operating margin fell because staff costs, utility, fuel and power bills, and EU remediation consulting cost more. One-time TGA audit, European consulting, EU-GMP repairs and MIDC charges also weighed on it.

   Next results: check whether those one-time costs drop out next quarter.

   From the earnings call on 7 Aug 2026.

For April to June 2026 (the quarter ended 30 June 2026), Zim Laboratories reported revenue of ₹94.2 crore, up 31.2% from ₹71.8 crore a year earlier, and a loss of ₹4.02 crore.

Zim Laboratories results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Zim Laboratories' management discussed these results on a call held on 7 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Zim Laboratories closed at ₹134.43 on 4 November 2026, up 89.3% from ₹71.00 a year earlier (7 November 2025) and up 215.8% over five years. Its highest weekly close since September 2018 was ₹150.70 on 9 October 2026.

Zim Laboratories share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

433 weekly closes from 14 September 2018 to 4 November 2026.

4 Nov 2026: Zim Laboratories closed at ₹134.43, down 1.5% on the week and down 1.5% on the month. 7 Aug 2026: Zim Laboratories held its results call for April to June 2026. Management guided: Final EU GMP report hoped for within 1-2 weeks; CAPA submission ready immediately after receipt.

Earlier

• Results for April to June 2026: Revenue up 31.2% on a year earlier.

Zim Laboratories has paid no dividend on the NSE since 1 April 2021, the start of the period we checked.

Not in its latest year. Zim Laboratories Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 4 of its last 12 reported years, so there is a history but no current dividend.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 7 August 2026, Zim Laboratories' management guided: Final EU GMP report hoped for within 1-2 weeks; CAPA submission ready immediately after receipt.

“It is now only a question of timing. Hopefully, it will come soon enough, and then we can start generating revenues from the EU business.”Zulfikar Kamal, on the call for April to June 2026

What management guided

• EU supplies expected to start in Q4 if approval arrives in August; 8-10 product MAs expected after approval.
• FY27 revenue growth of 10-15% even if EU approval slips to FY28.
• FY28 revenue growth of 30-35% if EU approval and supplies start; 60-70% of growth attributed to EU.
• Gross margin around 55-58% from product mix; post-EU operating margin described as upper-teens then mid-teens; delayed-EU FY27 margins similar to prior year; Q1 one-time items not recurring next quarter.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 7 August 2026.

When Zim Laboratories reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Final EU-GMP report and CAPA acceptance - check whether the no-critical-observation path converts into formal recertification.

Zim Laboratories is on 2 of our India lists: Momentum stocks and Pharma stocks.

Zim Laboratories Ltd posted a net loss of ₹4.0 Cr in the Jun 2026 quarter. Full-year FY26 profit was ₹6.0 Cr. Over 10 years profit has grown 1.8% a year on average. That loss is 4.3% of the quarter's revenue. The same quarter a year earlier lost ₹1.9 Cr. 3 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹6.0 Cr (−50.0% on the year before).

On average over the last four quarters, profit changed −43.7% and revenue +9.3%. Profit is growing slower than sales: rising costs are taking part of the growth.

Zim Laboratories Ltd reported ₹94.2 Cr of revenue in the Jun 2026 quarter, +31.2% on the same quarter a year earlier. Over 10 years it has grown 3.4% a year on average. The last full year, FY26, came in at ₹374 Cr. The last four reported quarters add to ₹397 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹374 Cr, −1.3% on the year before.

Recent pace: the last four quarters grew +9.3% on average, against 3.4% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +7.6%, against +1.9% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −60.6%, against −54.6% a year (rolling over).

Zim Laboratories Ltd's operating margin was 2.6% in the Jun 2026 quarter, 3.3 percentage points lower than the same quarter a year ago. Across 12 years it has been between −4.4% and 13.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −3.3 percentage points on the year while gross margin changed −0.1 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 306% of Zim Laboratories Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹50.0 Cr of operating cash against ₹6.0 Cr of profit. After ₹44.0 Cr of spending on assets, ₹6.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 306% of profit came in as cash: the cash cycle got 90 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 3.2× depreciation over three years. The next section checks what that spending is building.

Zim Laboratories Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 152 days in FY26, up from 62 days in FY21. It spent ₹178 Cr on assets over the last 3 years. Customers take 106 days to pay, and stock sits for 207 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹374 Cr, each day of that cycle ties up about ₹1.0 Cr, so roughly ₹156 Cr is tied up in the business at any time.

FY26: customers took 106 days to pay and stock sat for 207 days, about 6.8 months of sales sitting as stock, for a full cycle of 152 days, longer than FY21's 62.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 207 days. Customers pay about 106 days after that. Suppliers are paid at 161 days. Together that makes the 152-day cycle.

Spending on assets: ₹178 Cr over the last 3 years, against ₹56.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹96.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Zim Laboratories Ltd's P/E is 195.7×, about the highest it has ever been. Its usual P/E (the middle reading) is 28.3×, over 7.9 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹0.76.

Why the multiple is where it is: over the past year earnings per share moved −56.4% while the price moved +89.3%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 5 years the price moved +25.9% a year; about −10.2% a year came from earnings growth and about +36.1 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Zim Laboratories Ltd's business is getting worse. Profit and EPS growth are shrinking: profit growth is −60.6% in the latest quarter, against −6.0% at its best in 12 quarters, with ROCE falling at 5.7%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Zim Laboratories Ltd earned a ROCE of 5% in FY26. Its return on capital used (ROIC) is 10.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 1.6% net margin and 0.69× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 1.6% net margin × 0.69× asset turnover × 1.81× leverage (assets divided by equity) ≈ 2.0% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 1.1% − 12.0% = −10.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

Zim Laboratories Ltd has total debt of ₹127 Cr against shareholder equity of ₹296 Cr as of Jun 2026, so its debt is 0.43× its equity. Year by year, that ratio went from 0.30 in FY22 to 0.43 in FY26. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.